(Reuters) – When the supply of COVID-19 antiviral drugs increases, the Biden administration will be looking for ways to expand access, according to the Wall Street Journal, citing a source with knowledge.

Administration is currently reviewing Paxlovid’s antiviral properties Pfizer The Journal reports that Inc (NYSE:) can become available in the retail market at pharmacies once it has received regulatory approval.

Molnupiravir, an oral pill from Merck & Co Inc and Ridgeback Biotherapeutics LP that is also under regulatory review, may be included in the government’s plan to make it commercially available, the journal reported, citing the person.

Pfizer has offered to purchase 10 million units of the drug from the United States. Merck has purchased 3.1 million of these pills. Current U.S. Food and Drug Administration is reviewing requests for an emergency authorization to the drug.

In response to a Reuters inquiry, Pfizer cited the supply agreement it made with the U.S. government on Thursday. Merck and U.S. Department of Health and Human Services did not respond immediately.

These drugs can be used to combat the current public health crisis. Countries are scrambling for supply agreements after receiving promising data from the companies.

According to the report by the U.S., drugmakers are being pushed to produce more, and commercial sales may occur when the supply increases.